1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 1,272 | 1,472 | 07:25 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 26.06. | XSpray Pharma AB: Xspray Pharma provides regulatory update on its US product candidates Nilopki and Dasynoc and notes continued progress with its third-party manufacturer NerPharMa | 206 | GlobeNewswire (Europe) | Xspray Pharma AB (publ) (Nasdaq Stockholm: XSPRAY) provides an update on the FDA review of its two US new drug applications. For Nilopki®, Xspray has defined an approach to address the items raised... ► Artikel lesen | |
| XSPRAY PHARMA Aktie jetzt für 0€ handeln | |||||
| 05.06. | XSpray Pharma AB: Xspray Pharma Receives CRL from U.S. FDA for Nilopki | 191 | GlobeNewswire (Europe) | Xspray Pharma AB (publ) (Nasdaq Stockholm: XSPRAY), a pharmaceutical company leveraging its proprietary HyNap technology platform to develop improved versions of marketed protein kinase inhibitors (PKIs)... ► Artikel lesen | |
| 03.06. | XSpray Pharma AB: Xspray Pharma employees fully participate in market priced long term incentive programs, signaling strong confidence ahead | 171 | GlobeNewswire (Europe) | Xspray Pharma's two newly implemented long-term incentive programs, LTIP 2025/2028 and LTIP 2026/2029, have reached full participation from the employees to whom they were offered. Participating employees... ► Artikel lesen | |
| 12.05. | XSpray Pharma AB: Bulletin from the annual general meeting of Xspray Pharma AB (publ) 12 May 2026 | 158 | GlobeNewswire (Europe) | The following resolutions were passed at the annual general meeting (the "AGM") of Xspray Pharma AB (publ) ("Xspray") on 12 May 2026.Adoption of income statement and balance sheet for the financial... ► Artikel lesen | |
| 28.04. | XSpray Pharma AB: Interim Report First Quarter 2026 | 270 | GlobeNewswire (Europe) | January-March 2026, GroupNet sales amounted to SEK 0 thousand (0)Earnings before tax amounted to SEK -35,380 thousand (-42,321)Earnings per share before dilution amounted to SEK -0.85 (-1.14)Cash flow... ► Artikel lesen | |
| 23.04. | XSpray Pharma AB: Xspray's rights issue oversubscribed - over-allotment issue fully utilized | 225 | GlobeNewswire (Europe) | THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA... ► Artikel lesen | |
| 14.04. | XSpray Pharma AB: FDA accepts trade name Nilopki for Xspray's drug candidate XS003 (nilotinib) | 773 | GlobeNewswire (Europe) | The US Food and Drug Administration (FDA) has accepted Nilopki® as the proprietary name for Xspray Pharma's drug candidate XS003 (nilotinib). Nilopki is an improved, amorphous formulation of nilotinib... ► Artikel lesen | |
| 31.03. | XSpray Pharma AB: Xspray publishes disclosure document regarding rights issue | 182 | GlobeNewswire (Europe) | THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA... ► Artikel lesen | |
| 31.03. | XFRA CAPITAL ADJUSTMENT INFORMATION - 31.03.2026 | 349 | Xetra Newsboard | Das Instrument OJ3 SE0009779796 SEAFIRE CAPITAL SK 10 EQUITY wird ex Kapitalmassnahme gehandelt am 31.03.2026 The instrument OJ3 SE0009779796 SEAFIRE CAPITAL SK 10 EQUITY is traded ex capital adjustment... ► Artikel lesen | |
| 26.03. | XSpray Pharma AB: Xspray receives additional subscription undertakings; rights issue now covered to 110% and over-allotment issue increased | 237 | GlobeNewswire (Europe) | THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA... ► Artikel lesen | |
| 24.03. | XSpray Pharma AB: Xspray resolves on a rights issue of approximately SEK 83 million with an over-allotment issue | 291 | GlobeNewswire (Europe) | THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA... ► Artikel lesen | |
| 11.03. | XSpray Pharma AB: Xspray Pharma: FDA accepts resubmitted application for market approval of Dasynoc - PDUFA date August 25, 2026 | 415 | GlobeNewswire (Europe) | The U.S. Food and Drug Administration (FDA) has accepted Xspray Pharma's resubmitted New Drug Application (NDA) for Dasynoc® for review under the 505(b)(2) procedure. The FDA has set a PDUFA date of... ► Artikel lesen | |
| 26.02. | XSpray Pharma AB: Xspray Pharma re-submits its FDA application for Dasynoc | 305 | GlobeNewswire (Europe) | Xspray Pharma AB (publ) has re-submitted its application for market approval for Dasynoc® to the U.S. Food and Drug Administration (FDA). Dasynoc® is the company's lead product candidate - an amorphous... ► Artikel lesen | |
| 26.02. | XSpray Pharma AB: Xspray Pharma appoints Blake Leitch as CEO - Per Andersson continues as Chief Scientific Officer (CSO) | 310 | GlobeNewswire (Europe) | The Board of Directors of Xspray Pharma has today appointed Blake Leitch as CEO of Xspray Pharma, effective no later than June 1, 2026. He brings over 20 years of international experience of marketing... ► Artikel lesen | |
| 12.02. | XSpray Pharma AB: Interim Report Fourth Quarter 2025 | 167 | GlobeNewswire (Europe) | October-December 2025, GroupNet sales amounted to SEK 0 thousand (0)Earnings before tax amounted to SEK -37,009 thousand (-82,002)Earnings per share before dilution amounted to SEK -0.89 (-2.36)Cash... ► Artikel lesen | |
| 05.11.25 | XSpray Pharma AB: Interim Report Third Quarter 2025 | 325 | GlobeNewswire (Europe) | July-September 2025, GroupNet sales amounted to SEK 0 thousand (0)Earnings before tax amounted to SEK -47,332 thousand (-82,272)Earnings per share before dilution amounted to SEK -1.25 (-2.44)Cash flow... ► Artikel lesen | |
| 08.10.25 | XSpray Pharma AB: Xspray Pharma provides update on the FDA process for Dasynoc - observations at contract manufacturer delay approval | 347 | GlobeNewswire (Europe) | • FDA has issued a Complete Response Letter (CRL) regarding Xspray Pharma's New Drug Application (NDA) for Dasynoc, referring to GMP (Good Manufacturing Practice) observations at a contract manufacturer.... ► Artikel lesen | |
| 11.09.25 | XSpray Pharma AB: Xspray's rights issue oversubscribed - over-allotment issue increased and fully utilized | 371 | GlobeNewswire (Europe) | THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEELAND, RUSSIA... ► Artikel lesen | |
| 26.08.25 | Listing of subscription rights and paid subscription shares of XSpray Pharma AB | 464 | GlobeNewswire | With effect from August 27, 2025, the subscription rights of XSpray Pharma AB will be traded on the list for Equity rights. Trading will continue up until and including September 04, 2025.
Instrument:
Subscription... ► Artikel lesen | |
| 25.08.25 | XSpray Pharma AB: Xspray publishes disclosure document regarding rights issue | 490 | GlobeNewswire (Europe) | THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEELAND, RUSSIA... ► Artikel lesen |
1 2 Weiter >>
25 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EVOTEC | 4,990 | +2,00 % | Hensoldt äußert sich zum Rheinmetall-Debakel! Power Metallic Mines Aktie vor Kursexplosion? Was macht Evotec? | Steht bei Power Metallic Mines eine Kursexplosion kurz bevor? Analysten sehen den fairen Wert des Multi-Metall-Explorers über 150 % höher. Im aktuellen Interview hat der CEO die Ressourcenschätzung... ► Artikel lesen | |
| BB BIOTECH | 55,50 | 0,00 % | BB Biotech hält dagegen | Die Schweizer Beteiligungsgesellschaft im Biotech-Sektor generiert mit dem Break bei 50 CHF ein neues Kaufsignal und stellt sich gegen den Gesamtmarkt der letzten 2 Tage. Aktueller Abschlag je Aktie... ► Artikel lesen | |
| MODERNA | 66,94 | -0,10 % | Märkte am Morgen: Apple, SanDisk, Tesla, Moderna, Bayer, Deutsche Bank, Rheinmetall, Thyssenkrupp | Was für ein Handelstag! Der DAX hat es gestern nicht nur geschafft die am Mittwoch eroberte Marke von 25.000 Punkten zu halten. Nach verhaltenem Start zog er immer dynamischer an und erreichte eine... ► Artikel lesen | |
| CRISPR THERAPEUTICS | 49,380 | +0,17 % | H.C. Wainwright reiterates CRISPR Therapeutics stock rating on label expansion | ||
| NANOREPRO | 2,170 | -1,36 % | NanoRepro: Attraktive Positionierung | Nach Darstellung der Analysten Matthias Greiffenberger und Cosmin Filker von GBC hat die NanoRepro AG die bisherige europäische Vertriebs- und Lizenzvereinbarung für das FiberSense-CGM-System in eine... ► Artikel lesen | |
| AAP IMPLANTATE | 1,550 | 0,00 % | EQS-HV: aap Implantate AG: Bekanntmachung der Einberufung zur Hauptversammlung am 23.06.2026 in Berlin mit dem Ziel der europaweiten Verbreitung gemäß §121 AktG | EQS-News: aap Implantate AG
/ Bekanntmachung der Einberufung zur Hauptversammlung
aap Implantate AG: Bekanntmachung der Einberufung zur Hauptversammlung am 23.06.2026 in Berlin... ► Artikel lesen | |
| INFLARX | 1,837 | +1,66 % | ANALYSE: InflaRx NV: Könnte die Aktie jetzt komplett einbrechen? - Was Sie jetzt noch wissen müssen | ||
| TEMPUS AI | 53,79 | -0,02 % | Freedom Capital Initiates Coverage of Tempus AI, Inc. (TEM) | ||
| EDITAS MEDICINE | 2,910 | +1,04 % | Editas Medicine, Inc.: Editas Medicine Reports New Preclinical Data Demonstrating Progress of EDIT-401 as Potential Treatment for Hyperlipidemia at the American Society of Gene and Cell Therapy 2026 Annual Meeting | CAMBRIDGE, Mass., May 14, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company developing transformative medicines for serious diseases, shared new preclinical... ► Artikel lesen | |
| BIOMARIN PHARMACEUTICAL | 52,40 | 0,00 % | BioMarin Pharmaceutical Inc.: BioMarin Announces Positive Phase 3 Pivotal Study Results for VOXZOGO (vosoritide) in Children with Hypochondroplasia | Study met primary endpoint, exceeding expectations with a highly statistically significant improvement in annualized growth velocity (AGV, change from baseline)... ► Artikel lesen | |
| CARDIOL THERAPEUTICS | 0,880 | +1,03 % | Cardiol Therapeutics Inc. - 6-K, Report of foreign issuer | ||
| EVONEXT | 2,340 | 0,00 % | EvoNext Holdings SA: EvoNext shareholders approve all motions proposed by the Board at the Annual General Meeting 2026 | EvoNext Holdings SA
/ Key word(s): AGMEGM
EvoNext shareholders approve all motions proposed by the Board at the Annual General Meeting 2026
20.05.2026 / 17:01 CET/CEST
PRESS... ► Artikel lesen | |
| IDORSIA | 6,950 | +0,58 % | Besitzer Jean-Paul Clozel geht Wette ein: Baselbieter Biotechfirma Idorsia wagt den Neustart - mit neuem CEO und frischem Geld | ||
| MYRIAD GENETICS | 5,314 | 0,00 % | Myriad Genetics, Inc.: New Large-Scale Meta-Analysis Demonstrates Strong Prognostic Performance of Myriad's Prolaris Biopsy Test in Localized Prostate Cancer | SALT LAKE CITY, July 02, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announces newly published data from the... ► Artikel lesen | |
| ALDEYRA | 1,870 | -6,50 % | Aldeyra appoints Darlene Deptula-Hicks to board of directors |
XSPRAY PHARMA AB gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 1,288 Euro und damit 0,00 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu XSPRAY PHARMA AB finden Sie auf Wallstreet Online.